Giuseppe  Ciaramella net worth and biography

Giuseppe Ciaramella Biography and Net Worth

Insider of Beam Therapeutics
Giuseppe Ciaramella, Ph.D. has served as our Chief Scientific Officer since February 2018 and as our President and Chief Scientific Officer since January 2020. Dr. Ciaramella has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics, a biopharmaceutical company, from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, which technology formed the backbone of its authorized vaccine for the prevention of COVID-19. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, a biopharmaceutical company, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, a pharmaceutical company, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer, a biopharmaceutical company, in the U.K. where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London. Provided by Tagnifi.

What is Giuseppe Ciaramella's net worth?

The estimated net worth of Giuseppe Ciaramella is at least $1.27 million as of July 24th, 2023. Dr. Ciaramella owns 48,250 shares of Beam Therapeutics stock worth more than $1,273,800 as of December 9th. This net worth estimate does not reflect any other investments that Dr. Ciaramella may own. Additionally, Dr. Ciaramella receives a salary of $933,200.00 as Insider at Beam Therapeutics. Learn More about Giuseppe Ciaramella's net worth.

How old is Giuseppe Ciaramella?

Dr. Ciaramella is currently 54 years old. There are 2 older executives and no younger executives at Beam Therapeutics. Learn More on Giuseppe Ciaramella's age.

What is Giuseppe Ciaramella's salary?

As the Insider of Beam Therapeutics Inc., Dr. Ciaramella earns $933,200.00 per year. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $1,110,000.00 per year. Learn More on Giuseppe Ciaramella's salary.

How do I contact Giuseppe Ciaramella?

The corporate mailing address for Dr. Ciaramella and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on Giuseppe Ciaramella's contact information.

Has Giuseppe Ciaramella been buying or selling shares of Beam Therapeutics?

Giuseppe Ciaramella has not been actively trading shares of Beam Therapeutics during the last ninety days. Most recently, Giuseppe Ciaramella sold 1,206 shares of the business's stock in a transaction on Monday, July 24th. The shares were sold at an average price of $32.01, for a transaction totalling $38,604.06. Following the completion of the sale, the insider now directly owns 48,250 shares of the company's stock, valued at $1,544,482.50. Learn More on Giuseppe Ciaramella's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 284,412 shares worth more than $10,417,585.03. The most recent insider tranaction occured on October, 30th when insider Amy Simon sold 3,448 shares worth more than $64,477.60. Insiders at Beam Therapeutics own 4.4% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 10/30/2023.

Giuseppe Ciaramella Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2023Sell1,206$32.01$38,604.0648,250View SEC Filing Icon  
7/21/2023Sell155,324$32.06$4,979,687.4448,250View SEC Filing Icon  
4/3/2023Sell1,918$30.31$58,134.58114,044View SEC Filing Icon  
12/12/2022Sell51,015$42.70$2,178,340.5091,462View SEC Filing Icon  
3/31/2022Sell1,859$59.11$109,885.49115,614View SEC Filing Icon  
12/21/2021Sell25,104$85.69$2,151,161.76View SEC Filing Icon  
6/28/2021Sell78,580$107.35$8,435,563.00123,341View SEC Filing Icon  
See Full Table

Giuseppe Ciaramella Buying and Selling Activity at Beam Therapeutics

This chart shows Giuseppe Ciaramella's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $26.40
Low: $26.29
High: $28.79

50 Day Range

MA: $23.95
Low: $17.69
High: $30.76

2 Week Range

Now: $26.40
Low: $16.95
High: $51.60


1,780,125 shs

Average Volume

1,444,542 shs

Market Capitalization

$2.15 billion

P/E Ratio


Dividend Yield